182352-48-3

Usage

Uses

Used in Pharmaceutical Research:
2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester is used as a biochemical tool for research purposes in the field of pharmaceuticals. Its unique properties make it of interest in the development of new drug compounds.
Used in Organic Synthesis:
2,5-Dihydro-4-hydroxy-2-oxo-1H-pyrrole-1-carboxylic acid 1,1-dimethylethyl ester is used as a key intermediate in the synthesis of various organic compounds, contributing to the advancement of chemical research and development.
Used in Disease Treatment:
Although not explicitly stated in the provided materials, the compound's potential applications in the treatment of certain diseases suggest that it could be used as a therapeutic agent in the medical field, pending further research and development.

InChI:InChI=1/C9H13NO4/c1-9(2,3)14-8(13)10-5-6(11)4-7(10)12/h4,11H,5H2,1-3H3

Upstream product

• 4530-20-5 BOC-glycine 
• 2033-24-1 cycl-isopropylidene malonate 
• 108-23-6 isopropyl chloroformate 
• 182352-25-6 5-(N-tert-butoxycarbonyglycyl)meldrum’s acid 

Downstream Products

• 1161439-78-6 1-(tert-butoxycarbonyl)-4-hydroxy-3-(4′-methoxyphenyl)-1H-pyrrol-2(5H)-one 
• 928215-97-8 4-(4-chlorophenyl)-2-oxo-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 
• 928215-95-6 tert-butyl 2,5-dihydro-4-(4'-methoxyphenyl)-2-oxo-1H-pyrrole-1-carboxylate 
• 928215-96-7 2-oxo-4-phenyl-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 
• 443680-33-9 2-oxo-4-(toluene-4-sulfonyloxy)-2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Efficient total synthesis of pulchellalactam, a CD45 protein tyrosine phosphatase inhibitor

A new approach to a CD45 protein tyrosine phosphatase inhibitor, pulchellalactam, is described. The key step of the sequence involves addition and elimination of an enolic lactam in a single step and 70% yield, employing an organocuprate reagent. The resulting α,β-unsaturated lactam could be condensed with isobutyraldehyde to produce Z-pulchellalactam or converted into siloxypyrrole, which was subjected to the BF3·Et2O-promoted coupling reaction with isobutyraldehyde to afford E-pulchellalactam after E1-cB elimination and TFA deprotection. This first total synthesis afforded Z-pulchellalactam in six steps and 32% overall yield from Boc-glycine. The same sequence of reactions could also be applied to the liquid- or solid-phase synthesis of trifunctionalized pulchellalactam derivatives.

Short synthesis of 4-aryl-3-pyrrolin-2-ones

A three step, convergent synthesis of 4-aryl-3-pyrrolin-2-ones from a tetramic acid has been developed. The key transformation utilized a Suzuki-Miyaura cross-coupling reaction between a 4-tosyloxy-3-pyrrolin-2-one and an arylboronic acid. This work also

COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS

Provided are methods for treating neurological disorders using compounds of Formula (I), and pharmaceutically acceptable salts and compositions thereof.

METHODS AND COMPOSITIONS FOR MODULATING SPLICING

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

P300/CBP HAT INHIBITORS

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

TAMBJAMINES AND B-RING FUNCTIONALIZED PRODIGININES

Embodiments of tambjamines and B-ring functionalized prodiginines are disclosed. Methods of synthesizing and using the disclosed compounds are also disclosed. Some embodiments of the disclosed compounds have antimalarial activity. Certain embodiments of t

Synthesis and Structure-Activity Relationships of Tambjamines and B-Ring Functionalized Prodiginines as Potent Antimalarials

Synthesis and antimalarial activity of 94 novel bipyrrole tambjamines (TAs) and a library of B-ring functionalized tripyrrole prodiginines (PGs) against a panel of Plasmodium falciparum strains are described. The activity and structure-activity relationsh

Synthesis of fluorinated tricyclic scaffolds by intramolecular [2+2] photocycloaddition reactions

Fabulous Fluorine: The synthesis of fluorinated products 1 and 2 by [2+2] photocycloaddition was readily feasible after optimization of the irradiation conditions. The electron-deficient trifluoroolefin unit reacted intramolecularly to products 1 (nine ex